FIGURE 1.

Peanut allergy prevalence at 3–5 years of age—(A) Intention‐to‐treat and (B) per‐protocol populations. Prevalence of peanut allergy in each randomized treatment group is shown within individual and combined studies in (A) ITT analysis and (B) PP analysis. Number of peanut allergy (PA) and total number of participants (N) are annotated at the top. Each bar is annotated with the prevalence of peanut allergy as determined by OFC at 3 years (EAT) or 5 years of age (LEAP); relative risk reduction in individual and combined studies is annotated in red. Pearson's chi‐squared was used to determine annotated p‐values; when expected values were less than 5, Fisher's two‐tailed exact test was used. Fisher's p‐value is reported for the EAT PP analysis.